Get the Stockscreener App
11.62
3.17%
-0.38
Pre-market:
11.58
-0.04
-0.34%
Intellia Therapeutics Inc stock is traded at $11.62, with a volume of 2.93M.
It is down -3.17% in the last 24 hours and up +1.66% over the past month.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$12.00
Open:
$11.88
24h Volume:
2.93M
Relative Volume:
0.54
Market Cap:
$1.35B
Revenue:
$52.86M
Net Income/Loss:
$-480.19M
P/E Ratio:
-2.4777
EPS:
-4.6899
Net Cash Flow:
$-421.82M
1W Performance:
+4.78%
1M Performance:
+1.66%
6M Performance:
+7.00%
1Y Performance:
+22.19%
1-Day Range:
$11.21
$11.95
1-Week Range:
$11.21
$12.54
52-Week Range:
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
11.62 | 1.39B | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-11-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-28-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-27-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-27-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-05-25 | Initiated | H.C. Wainwright | Buy |
| Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
Will Intellia Therapeutics Inc. stock reach Wall Street targets2025 Biggest Moves & Daily Profit Maximizing Tips - mfd.ru
Should you avoid Intellia Therapeutics Inc. stock right nowJuly 2025 Selloffs & AI Powered Market Entry Ideas - baoquankhu1.vn
A Look At Intellia Therapeutics (NTLA) Valuation After FDA Lifts Clinical Hold On Key Phase 3 Trial - Sahm
Gene Editing Market Growth in Future Scope 2026-2033| CRISPR - openPR.com
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Hold" by Analysts - MarketBeat
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy? - AOL.com
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy? - The Motley Fool
Intellia Therapeutics (NTLA) Awards Inducement Grants to New Emp - GuruFocus
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia Therapeutics, Inc. $NTLA Shares Bought by IQ EQ FUND MANAGEMENT IRELAND Ltd - MarketBeat
Best Gene-Editing Stocks of 2026: Are They Right for Your Portfolio? - The Motley Fool
The Best Biotech Stocks to Buy - Morningstar
Intellia Therapeutics: 2 Major Catalysts Will Determine Stock Trajectory In 2026 (NTLA) - Seeking Alpha
Notable Two Hundred Day Moving Average CrossNTLA - Nasdaq
Intellia Therapeutics Receives Key Regulatory Clearance for Clinical Trial - AD HOC NEWS
Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip - MSN
Intellia Therapeutics (NTLA) Price Target Increased by 35.10% to 23.94 - Nasdaq
The Technical Signals Behind (NTLA) That Institutions Follow - Stock Traders Daily
Intellia Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Benchmark - Investor's Business Daily
FDA Clears Intellia Phase 3 ATTRv PN Trial Lifting Key Overhang - Sahm
FDA Lifts Hold On Intellia Trial Refocusing Attention On Valuation Upside - Yahoo Finance
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Clinical Hold On Key Phase 3 Trial - Yahoo Finance
FDA Lifts MAGNITUDE-2 Hold Refocusing Intellia’s ATTR Value Story - Sahm
Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal - Finviz
Baird Updates Intellia Therapeutics, Inc. (NTLA)’s Financial Model Following Nex-Z Clinical Hold Removal - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Aprea Therapeutics (APRE) - The Globe and Mail
The week in pharma: action, reaction and insight – week to January 30, 2026 - The Pharma Letter
Travel Stocks: Is Intellia Therapeutics Inc a top pick in the sectorRecession Risk & Daily Entry Point Trade Alerts - baoquankhu1.vn
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Hold On MAGNITUDE-2 Trial - Sahm
Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE - RTTNews
Intellia’s NTLA-2001 Hits Key Milestone in ATTR Gene-Editing Trial, Raising the Stakes in Amyloidosis - TipRanks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA) and Viridian Therapeutics (VRDN) - The Globe and Mail
Why Intellia Therapeutics (NTLA) Is Down 12.6% After FDA Lifts Hold On Key CRISPR Trial - Sahm
FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials - NeurologyLive
Breaking Down Intellia Therapeutics: 11 Analysts Share Their Views - Benzinga
Intellia Therapeutics (NASDAQ:NTLA) Trading Down 6.6%Time to Sell? - MarketBeat
NTLA Stock Rating Maintained and Price Target Raised by HC Wainw - GuruFocus
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold - Finviz
Y Intercept Hong Kong Ltd Makes New $2.37 Million Investment in Intellia Therapeutics, Inc. $NTLA - MarketBeat
H.C. Wainwright raises Intellia Therapeutics stock price target on clinical hold lift - Investing.com Canada
Brokers Offer Predictions for NTLA FY2030 Earnings - MarketBeat
Intellia Gets Nex-z Phase III Study Boost After FDA Lifts Clinical Hold - Citeline News & Insights
Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? - Yahoo Finance
Intellia Therapeutics - The Pharma Letter
FDA Clears MAGNITUDE-2 Hold Leaving Intellia Cardiomyopathy Questions Open - Yahoo Finance
Intellia Therapeutics to resume dosing of gene therapy in Phase III trial - Clinical Trials Arena
Intellia gets FDA nod to resume one gene therapy trial after safety pause - ET Pharma
Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug - MSN
Intellia’s nex-z moves ahead, but only for ATTR-PN for now - BioWorld MedTech
FDA Lifts Hold on Intellia's Nexiguran Ziclumeran Program (NTLA) - GuruFocus
Can Intellia Therapeutics Inc. sustain its profitabilityTrend Reversal & Risk Adjusted Buy and Sell Alerts - mfd.ru
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):